A class of 2′-fluoro-
nucleoside compounds are disclosed which are useful in the treatment of
hepatitis B infection,
hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and
cancer. The compounds have the general formulae: wherein[0001]Base is a
purine or
pyrimidine base;[0002]R1 is OH, H, OR3, N3, CN,
halogen, including F, or CF3, lower
alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a
purine or
pyrimidine base;[0003]R2 is H,
phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized
phosphate prodrug; acyl, or other pharmaceutically acceptable
leaving group which when administered
in vivo, is capable of providing a compound wherein R2 is H or
phosphate;
sulfonate ester including
alkyl or arylalkyl
sulfonyl including methanesulfonyl, benzyl, wherein the
phenyl group is optionally substituted with one or more substituents as described in the definition of
aryl given above, a lipid, an
amino acid,
peptide, or
cholesterol; and[0004]R3 is acyl,
alkyl, phosphate, or other pharmaceutically acceptable
leaving group which when administered
in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.